Brief: Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
May 14 (Reuters) - Zai Lab Ltd 9688.HK :
* ZAI LAB ANNOUNCES ACCEPTANCE OF SUPPLEMENTAL BIOLOGICS
LICENSE
APPLICATION WITH PRIORITY REVIEW FOR EFGARTIGIMOD ALFA INJECTION
(SUBCUTANEOUS INJECTION) IN CHRONIC INFLAMMATORY DEMYELINATING
POLYNEUROPATHY (CIDP) IN CHINA
* ZAI LAB LTD -SBLA SUBMISSION BASED ON POSITIVE RESULTS
FROM
ADHERE TRIAL
Source text for Eikon: ID:nBw1PgjfPa
Further company coverage: 9688.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zai Lab
See all newsBrief: Zai Lab Says ZL-1503 Was Well Tolerated With No Serious Adverse Events
Brief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows